Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

A 4 Week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

The purpose of this study is to study efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease

Inclusion Criteria:

• FEV1 between 30 and 80% of predicted normal value post-bronchodilator (GOLD stages 2 and 3)
• Clinical diagnosis of COPD

Exclusion Criteria:

• Other clinically relevant disease or disorders
• Exacerbation of COPD within 30 days